Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 14/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15485284 | 0.91 | CDK8 (0.63) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1781766 | 0.87 | RAF1 (0.52) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1012719 | 0.85 | MAPK13 (0.78) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL15492502 | 0.83 | MAPK14 (0.55) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1780615 | 0.79 | KCNJ6 (0.67) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL15516841 | 0.78 | CDK8 (0.63) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL20569742 | 0.78 | MAP3K7 (0.61) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL17911686 | 0.77 | MAPK13 (0.48) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL15717788 | 0.77 | NTRK1 (0.85) | GAANTRK1HPGD | |
| SCHEMBL25793170 | 0.77 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |